Optinose , a pharmaceutical company that focuses on treatments for ear, nose, and throat issues as well as allergies, has announced that the U.S. Food and Drug Administration has granted approval for XHANCE®

Sino Biological, Inc., a major biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, has forged a notable partnership with Rapid Novor, Inc, headquartered in Toronto

ProteoNic Biosciences, a leader in vector technology and services for biologics production, has announced a partnership with Ginkgo Bioworks, known for its advancements in cell programming and biosecurity

Arctic Therapeutics ehf, an Icelandic drug development company, in collaboration with Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in treatments for retinitis pigmentosa

Boehringer Ingelheim and Sosei Group Corporation have recently announced a global collaboration and an exclusive option-to-license agreement. The primary goal of this partnership

Eilean Therapeutics LLC, a biopharmaceutical company focusing on discovering and developing small molecule inhibitors for hematologic and solid malignancies, has announced a significant milestone.

Regeneron Pharmaceuticals, Inc. recently made a significant announcement regarding pediatric healthcare. The U.S. Food & Drug Administration has extended the approval of Praluent®

Apex Labs Ltd., a pharmaceutical company at the forefront of mental health treatment using psilocybin, is excited to announce the submission of a provisional patent application to the United States Patent and Trademark Office

Mind Medicine Inc., a company specializing in the development of treatments for brain health disorders, has received a breakthrough designation from the FDA for its MM120 program aimed at treating generalized anxiety disorder

Ludwig Enterprises, Inc, a US-based biotechnology company, is excited to announce the successful filing of its provisional patent titled "mRNAs Differentially Expressed in Colorectal Cancer,